Cipla introduces a diagnostic device for a variety of medical conditions

Cipla, a pharmaceutical company, announced the launch of a diagnostic device for a variety of conditions such as diabetes, infectious diseases, and thyroid function. Cippoint, a point-of-care testing device, offers a wide range of testing parameters, including cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers, according to a statement from the Mumbai-based drug maker. According to the company, the device is approved by the European In-Vitro Diagnostic Device Directive, which ensures reliable testing solutions.

"We are actively working to deliver innovative solutions that enable rapid and accurate diagnosis, thereby filling gaps in the diagnostic ecosystem. This advancement strengthens our vision of assisting patients throughout the healthcare continuum "Achin Gupta, CEO of Cipla One India Business, stated. The device, according to the company, expands the firm's product offerings for diagnostics laboratories and aims to bridge the current gap in the diagnostic ecosystem in India by providing reliable and accurate tests at affordable prices. Cippoint will enable healthcare professionals to receive test results in 3 to 15 minutes, allowing for faster clinical decision-making.

According to Cipla, Cippoint has an automated system and user-friendly interface that can be used even in rural areas, mobile vans, and remote areas with limited infrastructure.